![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Single Dose of Pfizer/BioNTech Vaccine Demonstrates Clear Immunity, UK Study Says
Single Dose of Pfizer/BioNTech Vaccine Demonstrates Clear Immunity, UK Study Says
![Vaccine needle](https://www.fdanews.com/ext/resources/test/Drug-Images4/Vaccine-needle-bottle.gif?t=1596243581&width=430)
March 30, 2021
A new UK study shows that one dose of the Pfizer-BioNtech COVID-19 vaccine offers as much immunity to the virus as having previously had a COVID infection.
The as-yet unpublished, nonpeer-reviewed study in The Lancet also showed increased immunity after the shot among those who had already had COVID-19, with a T-cell response that was around six times higher than those who were COVID-19-naive after their shot.
The study also showed that the Pfizer-BioNtech shot could offer immunity to new variants to those who have already had COVID.
Led by Sheffield and Oxford Universities with support from the UK Coronavirus Immunology Consortium, the study analyzed blood from 237 healthcare workers and found that the antibody and T-cell responses in those who had not previously had COVID-19 resembled those generated by natural infection.
Upcoming Events
-
21Oct